title: Effect of a venotonic agent on the main arteries and veins during a 5 day HDT.
abstract: OBJECTIVE
  To evaluate the cardiac, arterial and venous effect of a venotonic drug (Cirkan "Ck") administrated orally daily to 6 subjects in HDT position during 5 days. These subjects underwent a second 5d HDT without Ck treatment one month later. Pre and post HDT the subjects were submitted to a stand test.
  
  
  METHODS
  The cardiovascular parameters were measured by echography and Doppler.
  
  
  CONCLUSIONS
  The Cirkan treatment contributed to reduce the increase in cerebral resistance, and to maintain the lower limb resistance at a higher level than on controls. It reduces the vein section at the extremities (Jugular, femoral) and in the central vein system connected to the right heart (sub hepatics). On the other hand it increases the portal vein section which means that the blood stagnation at the splanchnic level is increased. Despite these arterial and venous significant modifications the clinical and ECG and Blood pressure response to the Stand test was similar in both groups.
authors.affiliation: Medecine & Physiologie Spatiale (UMPS), CHU Trousseau, 37044 Tours, France.
authors.forename: J
authors.initials: J
authors.lastname: Roumy
authors.forename: S
authors.initials: S
authors.lastname: Herault
authors.forename: N
authors.initials: N
authors.lastname: Tobal
authors.forename: S
authors.initials: S
authors.lastname: Besnard
authors.forename: P
authors.initials: P
authors.lastname: Arbeille
mesh_terms: D001205:Ascorbic Acid / Q000494:pharmacology*; D001510:Bed Rest; D002918:Chymotrypsin / Q000494:pharmacology*; D004338:Drug Combinations; D004487:Edema / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D005268:Femoral Vein / Q000033:anatomy & histology / Q000187:drug effects; D018495:Fluid Shifts / Q000187:drug effects* / Q000502:physiology; D018475:Head-Down Tilt / Q000009:adverse effects / Q000502:physiology*; D006321:Heart / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects*; D006569:Hesperidin / Q000494:pharmacology*; D006801:Humans; D007024:Hypotension, Orthostatic / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D007601:Jugular Veins / Q000033:anatomy & histology / Q000187:drug effects; D007866:Leg / Q000098:blood supply; D010840:Phytosterols / Q000494:pharmacology*; D011169:Portal Vein / Q000033:anatomy & histology / Q000187:drug effects; D013152:Splanchnic Circulation / Q000187:drug effects; D014357:Trypsin / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects*; D016277:Ventricular Function, Left / Q000502:physiology; D018474:Weightlessness Simulation
chemical_list: D004338:Drug Combinations; D010840:Phytosterols; C021980:hesperidine methylchalcone, ruscus aculeatus, vitamin C; D006569:Hesperidin; D002918:Chymotrypsin; D014357:Trypsin; D001205:Ascorbic Acid